Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Gerd Munzert"'
Autor:
Alexey V. Salnikov, Johannes Duell, Michel Attal, Alex C. Minella, Erik Rasmussen, Jan Krönke, Thierry Facon, Robin Lesley, Philippe Moreau, Christian Langer, Karl Beutner, Gerhard Zugmaier, Gerd Munzert, Max S. Topp, Kathrin Riemann, Hermann Einsele, James Kalabus
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e18-e19
Autor:
Martin Schuler, Beatrice Wehler, Kurt Werner Schmid, Martin Sebastian, J. Wohlschläger, Stefan Kasper, Daniela Westerwick, Birgit Gaschler-Markefski, Arno Schad, Gerd Munzert, Martin Werner, Karl Worm, Alicia Morresi-Hauf, Joachim von Pawel, Saskia Ting, Frank Breitenbuecher, Cornelius Kortsik
Background: Polo like kinase 1 (PLK1) is frequently upregulated in tumors and is thus viewed as a promising therapeutic target in various cancers. Several PLK1 inhibitors have recently been developed and clinically tested in solid cancers, albeit wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88233e25fdcedd25c30c20e3ea4c6154
https://www.ncbi.nlm.nih.gov/pubmed/28628916
https://www.ncbi.nlm.nih.gov/pubmed/28628916
Autor:
Johannes Duell, Christian Langer, Philippe Moreau, Jan Kroenke, Alex C. Minella, Erik Rasmussen, Robin Lesley, Kathrin Riemann, Max S. Topp, Karl Beutner, James Kalabus, Hermann Einsele, Michel Attal, Alexey V. Salnikov, Thierry Facon, Gerhard Zugmaier, Gerd Munzert
Publikováno v:
Journal of Clinical Oncology. 37:8007-8007
8007 Background: Objectives of this study included assessing safety and activity of AMG 420/BI 836909, which binds BCMA (B-Cell Maturation Antigen) on MM cells and CD3 on T cells, in relapsed and/or refractory (R/R) MM. Methods: In this FIH study, 6-
Autor:
Gerhard Zugmaier, Gerd Munzert, Michel Attal, Johannes Duell, Christian Langer, Max S. Topp, Jan Kroenke, Philippe Moreau, Hermann Einsele, Thierry Facon
Publikováno v:
Blood. 132:1010-1010
Background: BCMA, a member of the TNF receptor family, is expressed on MM and plasma cells. AMG 420, formerly BI 836909, binds BCMA on tumor cells and plasma cells and CD3 on T cells, resulting in T-cell mediated lysis of BCMA+ cells. Objectives of t
Autor:
Mark A. Socinski, Quincy Chu, Leena Gandhi, Joe Stephenson, David M. Ellison, Mark M. Awad, Ramaswamy Govindan, Holger Fritsch, Gerd Munzert, Philip Bonomi, Daniel S. Bradford, Keith D. Eaton, Bruce E. Johnson
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 104
Objectives This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed small cell lung cancer (SCLC). Secondary endpoints included progression-free
Autor:
Claude Petit, Vasthala Juvvigunta, Julie M. Vose, Holger Fritsch, Edmund K. Waller, Jonathan W. Friedberg, Anas Younes, Gerd Munzert, Bruce D. Cheson
Publikováno v:
Leukemia & Lymphoma. 54:708-713
Polo-like kinase 1 (Plk1) is expressed during mitosis and overexpressed in multiple cancers, including non-Hodgkin lymphoma (NHL). This phase I study determined the maximum tolerated dose (MTD) of BI 2536, a Plk1 inhibitor, as a 1 h infusion once eve
Autor:
Jochen Schütte, Frank Fleischer, Dirk Strumberg, Klaus Mross, M Merger, W E Aulitzky, Roland M Schmid, Max E. Scheulen, S Hollerbach, Gerd Munzert, Christian Dittrich
Publikováno v:
British Journal of Cancer
Background: BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas. Methods: The study employed a two-stage design. Randomised first-line patients received BI 2536 20
Autor:
Khalid Alsaleh, Brian L. Harry, Dirk Trommeshauser, C. Quinton, A. Frost, Peter M. Ellis, M.L. Smith, Ricardo Moro, Harmanjatinder S. Sekhon, W. Geddie, J. Gulyaeva–Tcherkassova, P. Stieber, S. Steinbild, S.G. Eckhardt, Xiaomei Yao, Marcio M. Gomes, Jennifer R. Diamond, Ming Tsao, Gerd Munzert, S. Hedbom, C. Unger, Rolf Kaiser, James R. Burton, Christopher J. Allen, K. Mross, Arvind Dasari
Publikováno v:
Current Oncology. 19:66-69
Background: Of all mastectomy patients, 90% will use an external prosthesis where the standard of care uses a stock prosthesis that is purchased “off the shelf.” Our objectives were to determine patient demand for and perceived value of a custom
Autor:
Patrick Schöffski, Holger Fritsch, Patricia Glomb, Ahmad Awada, Pascal Wolter, Gerd Munzert, Herlinde Dumez, S. Bartholomeus, M. Taton, Thierry Gil
Publikováno v:
European Journal of Cancer. 48:179-186
Background Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk). This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of vola
Autor:
Alexander Staab, Gerd Munzert, Matthias Freiwald, Iñaki F. Trocóniz, Elena Soto, Christiane Doege
Publikováno v:
Cancer Chemotherapy and Pharmacology. 68:1517-1527
The aim of this investigation was to compare the performance of a commonly used semi-mechanistic model for drug-related neutropenia with other semi-mechanistic models published in the literature. After their implementation in NONMEM VI, five semi-mec